Randy Bell’s last pharmacy job was so disheartening, he left his chosen profession for seven years. And that’s not the half of it. It was a full year before his next career move — residential real estate — started generating positive income flow. So yes, you could say it’s a bit of an understatement when … Read More
Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 21 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More
In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a 198-bed, full-service, community and regional non-profit medical center located in the Northeast. After weeks of laying all the necessary groundwork to manage its 340B program, we began actively submitting eligible prescriptions this past January. By the end of Q1, the hospital’s 2023 340B savings … Read More
Why 340B vendors charging Percentage Of Revenue is wrong. From time to time, 340B hospitals are required to purchase non-eligible prescriptions at the Wholesale Acquisition Cost. When that happens, the costs of those medications often exceed reimbursement. Most 340B hospitals already operate on a loss-basis. Which is why, we believe, it’s so wrong for 340B … Read More
Shandra Bouzemann did not start working with ProxsysRx’s Pharmacy At DeSoto by choice. “I was a senior at Ole Miss in 2021, and we were asked to choose the pharmacy where we’d like to do rotations. Well naturally, I picked the one at Baptist Oxford, which was a three-minute drive from campus, and less than … Read More
To date, we’ve published a dozen posts either detailing, or mentioning-in-passing, the clinical and financial benefits a well-run Meds To Beds program offers hospitals and the patients they serve. Which is why we thought it was time to report some of the personal benefits our program delivers — with a handful of stories we’ve heard … Read More
In the past week, no less than three articles have called attention to the restrictions drug manufacturers have imposed to evade their legal responsibility to honor 340B program prescription discounts — as well as the impact those restrictions have had on 340B-eligible nonprofit entities’ ability to serve their patients and communities. “Don’t believe drug companies: … Read More
Since the advent of 340B ESP in 2020, drug manufacturers have imposed a raft of unlawful restrictions on 340B program savings. Nowhere have those restrictions been more punitive than with specialty pharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. 340B restrictions from the drug manufacturers’ perspective That said, … Read More
Just ask her, she’ll admit it: When Shequila worked at ProxsysRx’s Conway Medical Center (CMC) pharmacy, her boss had a habit of talking about her to other people in the company. Which explains why she got an email one day from Dawn Dobersztyn, asking, “Have you seen this job opening we just posted?” Seems that … Read More
Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. We’ve generated more than $500 million in 340B Savings and Revenue. And yet, we’ve never served (or seen) a 340B health system with … Read More
